DK1079849T3 - Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning - Google Patents

Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning

Info

Publication number
DK1079849T3
DK1079849T3 DK99926330T DK99926330T DK1079849T3 DK 1079849 T3 DK1079849 T3 DK 1079849T3 DK 99926330 T DK99926330 T DK 99926330T DK 99926330 T DK99926330 T DK 99926330T DK 1079849 T3 DK1079849 T3 DK 1079849T3
Authority
DK
Denmark
Prior art keywords
drugs
preparation
cytotoxic effect
hmg proteins
hmg
Prior art date
Application number
DK99926330T
Other languages
English (en)
Inventor
Alberto Bartorelli
Original Assignee
Sicor Soc It Corticosteroidi S
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sicor Soc It Corticosteroidi S filed Critical Sicor Soc It Corticosteroidi S
Application granted granted Critical
Publication of DK1079849T3 publication Critical patent/DK1079849T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/1703—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • A61K38/1709—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702—Regulators; Modulating activity

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Marine Sciences & Fisheries (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
DK99926330T 1998-05-19 1999-05-19 Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning DK1079849T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IT98MI001094A IT1299583B1 (it) 1998-05-19 1998-05-19 Uso di proteine hmg-i per la preparazione di medicamenti ad attivita' citotossica
PCT/EP1999/003431 WO1999059609A2 (en) 1998-05-19 1999-05-19 Use of hmg proteins for the preparation of medicaments having cytotoxic activity

Publications (1)

Publication Number Publication Date
DK1079849T3 true DK1079849T3 (da) 2002-04-22

Family

ID=11380053

Family Applications (1)

Application Number Title Priority Date Filing Date
DK99926330T DK1079849T3 (da) 1998-05-19 1999-05-19 Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning

Country Status (10)

Country Link
EP (1) EP1079849B1 (da)
JP (1) JP2002515445A (da)
AT (1) ATE211391T1 (da)
AU (1) AU4363199A (da)
DE (1) DE69900756T2 (da)
DK (1) DK1079849T3 (da)
ES (1) ES2171086T3 (da)
IT (1) IT1299583B1 (da)
PT (1) PT1079849E (da)
WO (1) WO1999059609A2 (da)

Families Citing this family (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6303321B1 (en) 1999-02-11 2001-10-16 North Shore-Long Island Jewish Research Institute Methods for diagnosing sepsis
US7151082B2 (en) 1999-02-11 2006-12-19 The Feinstein Institute For Medical Research Antagonists of HMG1 for treating inflammatory conditions
EP1192963A4 (en) * 2000-04-05 2004-08-25 Toray Industries ADSORBENTS FOR PROTEINS OF THE HIGH MOBILITY PROTEIN AND PILLAR GROUP FOR CLEANING BODY LIQUIDS
US7304034B2 (en) 2001-05-15 2007-12-04 The Feinstein Institute For Medical Research Use of HMGB fragments as anti-inflammatory agents
US7220723B2 (en) 2001-05-15 2007-05-22 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
ITMI20011986A1 (it) * 2001-09-25 2003-03-25 San Raffaele Centro Fond Metodo e composizione per l'attivazione di cellule presentanti l'antigene
AU2002358771B2 (en) * 2001-12-19 2009-04-23 Alcedo Biotech Gmbh Use of HMGB proteins and nucleic acids that code therefor
GB0226251D0 (en) * 2002-11-11 2002-12-18 San Raffaele Centro Fond Acetylated protein
US7696169B2 (en) 2003-06-06 2010-04-13 The Feinstein Institute For Medical Research Inhibitors of the interaction between HMGB polypeptides and toll-like receptor 2 as anti-inflammatory agents
CN1878793A (zh) 2003-09-11 2006-12-13 鉴定医疗有限公司 拮抗hmgb1的单克隆抗体
US8129130B2 (en) 2004-10-22 2012-03-06 The Feinstein Institute For Medical Research High affinity antibodies against HMGB1 and methods of use thereof
CN101132811B (zh) 2004-10-22 2012-05-30 米迪缪尼有限公司 抗hmgb1的高亲和力抗体及其用法
WO2007076200A2 (en) 2005-11-28 2007-07-05 Medimmune, Inc. Antagonists of hmgb1 and/or rage and methods of use thereof
EP2525817B8 (en) 2010-01-21 2017-09-20 The Board of Trustees of The University of Arkansas Vaccine vectors and methods of enhancing immune responses
HUE046858T2 (hu) 2010-06-09 2020-03-30 Univ Arkansas Vakcina és eljárások campylobacter fertõzés csökkentésére
MY173328A (en) 2013-02-14 2020-01-16 Texas A & M Univ Sys Compositions and methods of enhancing immune responses to eimeria or limiting eimeria infection
EA033538B1 (ru) 2013-03-15 2019-10-31 Univ Arkansas Композиции и способы усиления иммунного ответа на кишечные патогены
TWI758288B (zh) 2016-05-03 2022-03-21 阿肯色州大學董事會 包含免疫刺激性及抗原性多肽的酵母菌疫苗載體以及其使用方法

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS62166897A (ja) * 1986-01-20 1987-07-23 Toyo Soda Mfg Co Ltd 核内非ヒストン蛋白質に対するモノクロ−ナル抗体
EP0727487A1 (en) * 1995-02-17 1996-08-21 K.U. Leuven Research & Development Multiple-tumor aberrant growth genes
FR2739292B1 (fr) * 1995-09-28 1997-10-31 Rhone Poulenc Rorer Sa Composition pharmaceutique utile pour la transfection d'acides nucleiques et ses utilisations
JP3018313B2 (ja) * 1996-02-23 2000-03-13 雪印乳業株式会社 骨形成促進及び骨吸収防止剤

Also Published As

Publication number Publication date
EP1079849B1 (en) 2002-01-02
JP2002515445A (ja) 2002-05-28
DE69900756D1 (de) 2002-02-28
ES2171086T3 (es) 2002-08-16
DE69900756T2 (de) 2003-03-13
AU4363199A (en) 1999-12-06
EP1079849A2 (en) 2001-03-07
IT1299583B1 (it) 2000-03-16
PT1079849E (pt) 2002-06-28
WO1999059609A2 (en) 1999-11-25
WO1999059609A3 (en) 2000-01-27
ATE211391T1 (de) 2002-01-15
ITMI981094A1 (it) 1999-11-19

Similar Documents

Publication Publication Date Title
DK1079849T3 (da) Anvendelse af HMG-proteiner til fremstilling af lægemidler med cytotoksisk virkning
ATE254630T1 (de) Cyclosporine
EA200000331A1 (ru) Фармацевтические композиции, содержащие белок плазмы
HK1088840A1 (en) Stable analogs of glp-1 glp-1
BR9713404A (pt) ésteres de n-(aril/heteroarilacetil) aminoácidos, composições farmacêuticas compreendendo os mesmos, e métodos para a inibição da liberação de peptìdeo beta-amilóide e/ou de sua sìntese por uso de tais compostos.
DK0760677T3 (da) Farmaceutisk præparat omfattende glucagon
EA200300381A1 (ru) Нуклеиновые кислоты и полипептиды нового рецептора
NO20010995D0 (no) Cytotoksiske peptider modifisert med store eller lipofile rester
ES2103857T3 (es) Peptidos ciclicos y su uso.
DE60334773D1 (de) Formulierungen zur oralen verabreichung von wirkstoffen
PT848720E (pt) Antagonistas da actividade oncogenica da proteina mdm2 e sua utilizacao no tratamento de cancros
ATE398630T1 (de) Zyklische conotoxin-peptide
WO1999060013A3 (en) Il-6 antagonist peptides
DK1641820T3 (da) Fra RasGap afledt peptid til selektiv at dræbe kræftceller
BR0312889A (pt) Polipeptìdeo t20 peguilado
WO2003097677A3 (fr) Nouvelles compostions peptidiques et leur utilisation notamment dans la preparation de compositions pharmaceutiques actives contre le virus de l'hepatite c
NO20000424D0 (no) Streptograminer, deres fremstilling samt preparater inneholdende forbindelsene
PL355852A1 (en) Fragments of virus protein vp2 or 3 of the polyoma virus, used for transporting active ingredients
DE69434151D1 (de) Therapeutische inhaltsstoffe
WO2004111086A3 (fr) ANALOGUES PEPTIDIQUES COMPRENANT AU MOINS UN RESIDU AZA-ß3 AMINOACYLE, ET LEURS UTILISATIONS, NOTAMMENT EN THERAPIE
FI961505A0 (fi) Uudet veren koaguloitumisjärjestelmässä terapeuttisesti aktiiviset peptidiyhdisteet, menetelmä niiden valmistamiseksi ja niitä sisältävät farmaseuttiset koostumukset
WO2003089472A3 (en) Anti-nls scfv and peptides and uses thereof in nuclear import inhibition
WO1998051295A1 (fr) Inhibiteur de la protease du vih-1, leur procede de production, et compositions medicinales
CY1113593T1 (el) Σκευασματα ανταγωνιστη il-1
BR0215037A (pt) Composto, composição farmacêutica, e, uso de um composto